Extrahepatic malignancies and antiviral drugs for chronic hepatitis B: A nationwide cohort study.

Moon Haeng HurDong Hyeon LeeJeong-Hoon LeeMi-Sook KimJeayeon ParkHyunjae ShinSung Won ChungHee Jin ChoMin Kyung ParkHeejoon JangYun Bin LeeSu Jong YuSang Hyub LeeYong Jin JungYoon Jun KimJung-Hwan Yoon

Published in: Clinical and molecular hepatology (2024)

TDF was associated with approximately 30% lower risks of both EHM and IHM than ETV in CHB patients after 3 years of antiviral therapy.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
hepatitis b virus
prognostic factors
peritoneal dialysis
mesenchymal stem cells
human health
cell therapy
drug induced